bioAffinity Technologies, Inc.
BIAF
$0.4698
-$0.0292-5.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 269.68% | 2,814.72% | 30,256.85% | 86,531.58% | 52,660.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 269.68% | 2,814.72% | 30,256.85% | 86,531.58% | 52,660.42% |
| Cost of Revenue | 243.70% | 7,887.14% | 294,943.75% | 662,740.00% | 435,125.00% |
| Gross Profit | 326.79% | 1,237.79% | 11,434.22% | 31,126.92% | 17,890.91% |
| SG&A Expenses | 46.43% | 60.31% | 105.27% | 134.55% | 162.74% |
| Depreciation & Amortization | 142.53% | 455.27% | 886.58% | 1,167.11% | 2,982.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.34% | 133.86% | 168.20% | 174.33% | 161.61% |
| Operating Income | -12.29% | -15.09% | -46.05% | -72.67% | -98.79% |
| Income Before Tax | -14.05% | -16.79% | 11.45% | -1.83% | 2.89% |
| Income Tax Expenses | -44.29% | -25.13% | -17.96% | 6.61% | 740.00% |
| Earnings from Continuing Operations | -13.89% | -16.68% | 11.46% | -1.84% | 2.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.89% | -16.68% | 11.46% | -1.84% | 2.66% |
| EBIT | -12.29% | -15.09% | -46.05% | -72.67% | -98.79% |
| EBITDA | -8.08% | -8.43% | -38.71% | -65.92% | -93.05% |
| EPS Basic | 17.51% | 5.83% | 48.68% | 41.93% | 53.69% |
| Normalized Basic EPS | 17.42% | 5.77% | 48.70% | 44.72% | 55.59% |
| EPS Diluted | 17.51% | 5.83% | 48.68% | 41.93% | 53.69% |
| Normalized Diluted EPS | 17.42% | 5.77% | 48.70% | 44.72% | 55.59% |
| Average Basic Shares Outstanding | 38.58% | 26.34% | 33.03% | 53.60% | 94.48% |
| Average Diluted Shares Outstanding | 38.58% | 26.34% | 33.03% | 53.60% | 94.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |